Drugs Containing Excipient (Inactive Ingredient) STYRENE/ISOPRENE/STYRENE BLOCK COPOLYMER

Branded drugs containing STYRENE/ISOPRENE/STYRENE BLOCK COPOLYMER excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
MEDRx USA Inc	BONDLIDO	lidocaine	83708-111	STYRENE/ISOPRENE/STYRENE BLOCK COPOLYMER

Generic drugs containing STYRENE/ISOPRENE/STYRENE BLOCK COPOLYMER excipient

Company	Ingredient	NDC	Excipient
MEDRx USA Inc	lidocaine	83708-111	STYRENE/ISOPRENE/STYRENE BLOCK COPOLYMER

Last updated: May 30, 2026

STYRENE/ISOPRENE/STYRENE (SIS) Block Copolymer Excipient Market Dynamics and Financial Trajectory (2024–2035)

Executive summary: The pharmaceutical excipient market for styrene/isoprene/styrene (SIS) block copolymer is driven by demand for hot-melt and solid-dispersion systems in oral drug delivery and by pressure to replace older tackifier and polymer systems in pressure-sensitive, mucoadhesive, and film formulations. The revenue trajectory is supported by steady niche penetration rather than broad mass-market demand. Pricing power is constrained by petrochemical linkage (styrene, isoprene) and by availability of substitutes (SBR, hydrogenated SIS, HPMC-based systems, PVP/VA, Eudragit-type methacrylates). The highest value opportunity sits in higher-grade pharmaceutical grades, lower extractables compliance, and documentation-intensive commercialization in US/EU dossiers.

---

What drives demand for styrene/isoprene/styrene (SIS) block copolymer as a pharmaceutical excipient?

SIS is used as a film-former, tackifier, binder, and controlled-delivery component, most often in solid oral dosage forms and topical/adhesive platforms. Demand correlates more with formulation system upgrades than with new chemical entity cycles.

Primary demand channels

1. Hot-melt extrusion (HME) and melt-based granulation/binders
2. Oral solid formulations requiring adhesion, film integrity, or taste/texture control
3. Mucoadhesive drug delivery and oral films
4. Topical and transdermal adhesive layers (where SIS tack and elasticity are valued)
5. Controlled-release dispersion matrices where polymer chain flexibility supports drug release tuning

What formulation developers value

• Elastomeric flexibility and viscoelasticity
• Adhesion/tack without plasticizer migration (when using appropriate grades and process conditions)
• Compatibility with certain APIs and solvent systems (varies by API class and grade)
• Supply consistency for polymer MW distribution and functional performance

Regulatory/commercial friction points

• Documentation burden for pharmaceutical-grade materials (DMF in US, CEP-style expectations in EU, impurity and residual monomer control)
• Extractables/leachables and safety-by-design dossiers for adhesive and film applications
• Batch-to-batch performance and viscosity/MW consistency

---

How big is the pharmaceutical excipient market for SIS block copolymer, and how is it trending?

A complete public, product-specific market figure for “SIS block copolymer excipient” is typically not disclosed in industry reports at granular level because polymers are often grouped by polymer class or by end-use (adhesives, films, pharma excipients). Practical market sizing is therefore based on three observable proxies:

• Polymer grade procurement (pharma grades are smaller than industrial adhesive volumes)
• Documented usage in commercial formulations (film, adhesive, controlled-release)
• Supplier portfolio segmentation into pharma-grade vs industrial grade

Directional trend (2024–2035)

• Volume growth is expected to be moderate because SIS substitution risk is real and because pharma excipient switching requires dossier work.
• Value growth is expected to be stronger than volume because pharmaceutical-grade compliance, lower extractables variants, and stable supply command premium pricing.

Market structure

• SIS is supplied through specialized grades from polymer producers with pharma-grade documentation programs.
• Conversion into finished dosage forms is done by CMO CDMOs and formulation houses, where procurement is driven by dossier readiness and manufacturing constraints.

---

What is the pricing trajectory for SIS block copolymer excipient, and what moves it?

Key pricing drivers

1. Feedstock linkage
   • Styrene and isoprene pricing and volatility feed into SIS costs.
2. Energy and logistics
   • Solvent handling, pelletization, drying, and shipping impact cost base.
3. Grade differentiation
   • Pharmaceutical grades with controlled residual monomers, narrower MW distribution, and lower impurities price higher than industrial equivalents.
4. Demand cyclicality
   • Adhesives and coatings demand can pull volumes and prices, influencing availability for pharma grades.

Financial implication

• The financial trajectory of SIS-related pharma excipient revenue is likely to show pass-through behavior during feedstock spikes and margin compression when industrial demand weakens, unless pharmaceutical grade supply is constrained.

---

When does SIS block copolymer lose pricing power or margin, and why?

Margin pressure arrives when excipient substitution becomes easier or when competitor polymer systems gain formulation acceptance.

Typical erosion mechanisms

• Improved performance of alternatives such as:
  • hydrogenated SIS (when it offers better thermal stability)
  • SBR (styrene-butadiene rubber) or other elastomeric polymers
  • methacrylate-based film formers (Eudragit-type families)
  • cellulose and vinylpyrrolidone copolymers for certain oral film or binder roles
• Supplier capacity additions for industrial SIS grades (reducing feedstock-driven scarcity)
• Procurement shifts toward lower-cost compliant polymers during tender cycles

What prevents complete commoditization

• Hard-to-replicate polymer performance in specific dosage architectures
• Dossier timelines and the cost to run bridging studies after switching excipients
• Qualification requirements with extractables and residual monomer specifications

---

What excipient grades of SIS are used in pharma formulations, and how do they change performance?

SIS performance depends on:

• Block architecture and ratio (styrene end blocks vs mid isoprene block)
• Molecular weight distribution
• Residual monomer profile (styrene/isoprene, unreacted fractions)
• Stabilizers and antioxidants used to prevent oxidative degradation
• Hydrogenation status (where relevant)

Common pharma functionality mapping

• Adhesion/tack: depends on soft mid-block and end-block glass transition behavior
• Film integrity: controlled by elastic modulus and thermoplastic flow during processing
• Drug release control: influenced by polymer segment mobility and swelling behavior

Grade impact on documentation

• Pharma-grade specifications reduce regulatory risk but increase cost.
• Extractables and leachables studies are often grade-specific and processing-route dependent.

---

What patents protect SIS block copolymer excipient use in pharmaceutical formulations?

Patent landscapes for excipient use generally concentrate on:

• dosage form patents (films, mucoadhesive systems, controlled-release matrices)
• manufacturing methods and process parameters (HME formulations, adhesive layer casting, spray-drying variants)
• specific polymer blends and molecular weight ranges
• stability and performance claims tied to polymer selection

SIS itself is a widely known polymer, so protection often lies less in “SIS as a material” and more in:

• formulation compositions that use SIS at specific ratios
• methods of manufacture using SIS in controlled-process windows
• drug-polymer system performance (release profiles, adhesion metrics)

Practical legal implication

• In most commercialization cases, teams treat SIS selection as a formulation IP variable rather than as a standalone freedom-to-operate blocker, unless a formulation patent claims a specific SIS grade, MW, or blend recipe.

---

How strong is the patent estate for SIS-based pharmaceutical excipients versus polymer substitutes?

Relative strength

• SIS-based formulation patents tend to be:
  • narrower than drug substance patents
  • company-specific (tied to specific APIs and dosage architecture)
  • time-bound (expire with typical 20-year filings plus extensions)

Substitute risk

• Patent enforcement risk is typically higher for:
  • proprietary adhesive film and mucoadhesive platforms
  • controlled-release architectures with tight polymer composition windows
• Lower for generic “use SIS as binder/tackifier” concepts, unless explicitly claimed in a specific way.

Commercial impact

• For CDMOs and excipient buyers, the most actionable risk is not “SIS is patented,” but “this specific blend and dosage design is patented and currently licensed or under litigation.”

---

What patent litigation and licensing patterns affect SIS excipient adoption?

SIS typically enters patent disputes indirectly through:

• proprietary drug products and formulation platforms
• challenges to generic or biosimilar-type versions in dosage form, not excipient commodity

Common patterns

• Settlement agreements that lock in:
  • dosage form design changes
  • polymer system substitutions
  • manufacturing process modifications
• Licensing of formulation patents by generic entrants to avoid Paragraph IV-style exposure in certain jurisdictions and regulatory frameworks.

For an excipient buyer, the operational takeaway is that adoption barriers show up as:

• formulation redesign mandates
• bridging study requirements
• licensing costs embedded in contracted development

---

What is the Orange Book status of drug products that use SIS, and how does it affect excipient revenue?

Orange Book status is product-specific and varies by whether patents are listed for:

• active ingredient
• formulation and dosage
• methods of use

Because SIS is an excipient, its commercial effect is mediated by:

• patent expiry cycles of drug products using SIS
• degree of generic substitution in the dosage form that relies on SIS
• whether generics keep SIS or switch to substitutes to reduce litigation risk

Revenue dynamics linkage

• When product patents expire and generics launch, polymer sourcing often becomes:
  • more cost-optimized
  • performance-equivalent and regulatory-bridged
• If SIS remains best-performing for the generic, excipient revenue can stay stable.
• If litigation or cost pressure favors substitution, SIS share can decline even while total pharma excipient demand rises.

---

How do SIS excipients compare with hydrogenated SIS, SBR, and methacrylate film formers in pharma?

Performance comparison (typical formulation differences)

• SIS (not hydrogenated): higher elastomeric softness and tack; can be more sensitive to oxidative stability and temperature drift unless stabilized.
• Hydrogenated SIS: improved thermal and oxidative stability; can be preferred for longer shelf-life and higher processing temperatures, often at different rheology.
• SBR: broader industrial availability; lower pharma-grade premiums if compliant; performance depends on block architecture and glass transitions.
• Methacrylates (Eudragit-type): stronger documentation base for film-coating and controlled-release pH-responsive systems; may not match SIS tack/elasticity in mucoadhesive uses.

Commercial implication

• SIS competes on niche performance and elastic-film or adhesive behavior.
• Substitute selection often hinges on:
  • processing temperature window
  • extractables profile acceptability
  • required adhesion and patient comfort metrics

---

What FDA regulatory considerations shape SIS excipient commercialization in oral films and adhesives?

For excipient commercialization and use in marketed dosage forms:

• excipients generally rely on historical safety, pharmacopeial acceptability, or dossier-backed safety data
• pharma-grade specs must support impurity control and consistent performance
• extractables/leachables expectations rise for:
  • adhesive drug delivery
  • films with prolonged mucosal contact
  • systems with high polymer contact to the drug and/or environment

Regulatory friction points

• residual monomers and stabilizers
• batch variability and viscosity distribution
• stability under storage and accelerated conditions, especially when elastomeric polymers are involved

---

Which business risks matter most for SIS block copolymer excipient suppliers and investors?

1) Feedstock and margin volatility

• styrene/isoprene swings can compress margins or force price renegotiations.

2) Customer qualification cycles

• pharma-grade qualification and change control can delay pull-through demand.

3) Substitution and technology churn

• new excipient platforms can displace elastomeric systems if they reduce formulation development time or improve manufacturability.

4) Quality and compliance

• supply-chain traceability, residual impurity specs, and audit outcomes influence continued registrations and customer retention.

---

What commercialization timeline governs SIS excipient ramps in new drug products?

Typical adoption pathway:

1. Preformulation and feasibility (polymer screening, rheology, adhesion, compatibility)
2. Prototype formulation and process development
3. Stability and performance verification
4. Regulatory dossier inclusion for the finished dosage form
5. Scale-up and continuous supply qualification

The practical outcome is that SIS excipient revenue grows in steps, tied to dosage form launches and lifecycle changes, not continuous linear uptake.

---

How many drug products likely use SIS, and what does that mean for revenue concentration risk?

Public visibility for excipient-specific polymer use is limited unless disclosed in:

• formulation patents
• regulatory filings
• technical data packages shared by suppliers

Revenue concentration risk arises because:

• a small number of successful dosage forms can create a disproportionate share of pharma-grade SIS consumption
• supplier leverage can shift depending on whether customers treat SIS as best-in-class or as interchangeable

The most investable segments are those where SIS is essential to performance attributes (adhesion, elasticity) that are hard to replicate without redesign.

---

What generic entry risks exist for SIS-based dosage forms?

Generic risk is mainly tied to dosage form performance and patent coverage:

• If patents claim specific composition windows using SIS, generics must redesign.
• If no tight claims exist, generics may keep SIS and compete on cost.
• If litigation demands substitutions, SIS share can fall even after market entry.

Operational pattern

• For generics, the fastest path is to preserve excipient systems where:
  • performance is easiest to replicate
  • extractables and stability are already understood
• Slow path is required when:
  • dossier bridging is complex
  • patents require polymer or process change

---

What geographical and supply-chain factors affect SIS pharma excipient revenue?

Geography

• Demand for excipients is anchored to drug manufacturing hubs and to CDMO density.
• Regulatory expectations are highest in the US and EU, driving pharma-grade supply differentiation.

Supply-chain

• Chemical sourcing is globally distributed, but pharma-grade availability is more constrained because:
  • not all production lines produce compliant specs
  • certification and batch traceability are required
  • QA release testing and documentation increase friction

---

How does the SIS excipient financial trajectory vary by end use: oral films vs transdermal vs controlled-release?

Oral films / mucoadhesive

• Typically higher regulatory and formulation sensitivity.
• Revenue growth depends on pipeline launches of platform drugs and patient adherence-driven dosage trends.

Controlled-release matrices

• Adoption tied to specific release mechanism and stability windows.
• Longer product lifecycles can sustain polymer consumption.

Transdermal / adhesive layers

• More exposed to extractables/leachables and stability testing.
• If traction grows, it can drive steady demand but with higher qualification cost.

---

Key supply players and competitive landscape for SIS pharma excipient (2024–2035)

SIS is a commodity polymer in industrial markets, but pharma-grade is a differentiated supply category. The competitive set typically includes:

• polymer producers with pharma documentation programs
• hydrogenated SIS suppliers
• polymer distributors focused on dossier-ready grades

Competition tends to be won on:

• grade consistency and stability
• availability of documentation packages
• technical support for formulation developers

---

Key Takeaways

• SIS block copolymer excipient demand grows from niche dosage form needs, especially adhesive and film-type systems, not from broad single-mechanism replacement.
• Revenue trajectory is expected to be value-led (pharma-grade premium) with volume-led limits (substitution risk and qualification cycles).
• Pricing is dominated by feedstock volatility (styrene/isoprene), while margins depend on grade mix and pharma qualification retention.
• Patent and litigation effects generally manifest at the finished dosage form level; excipient switching can be driven by generic entry risk and formulation patent constraints.
• The strongest business case is supplying compliant pharma-grade SIS where performance attributes are difficult to replicate with alternatives (H-SIS, SBR, and methacrylates).

---

FAQs

1) Is SIS block copolymer used more in oral films or transdermal adhesives?
Use is driven by formulation performance needs; oral film/mucoadhesive and transdermal adhesive both value SIS elasticity and tack, with regulatory and extractables requirements typically higher for prolonged skin or mucosal contact.

2) What grade specs matter most for pharmaceutical SIS acceptance?
Residual monomers, MW distribution, impurity profile, stabilization system, and extractables/leachables compatibility under the intended process and storage conditions.

3) Can hydrogenated SIS replace SIS in pharma formulations without reformulation?
Often requires requalification because hydrogenation changes thermal behavior and rheology; reformulation or bridging studies are frequently needed for performance equivalence.

4) Do excipient patents block SIS procurement?
Rarely at the material level; barriers more often appear in dosage-form patents that claim specific polymer compositions and performance windows.

5) What drives SIS excipient price changes month-to-month?
Feedstock changes for styrene and isoprene, energy costs, and industrial polymer demand cycles that shift supply availability and grade allocation.

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. USP. (n.d.). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
3. European Medicines Agency. (n.d.). European public assessment reports and related guidance on excipients. European Medicines Agency.